SPR719

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H130282

CAS#: 1384984-18-2

Description: SPR719 is a bacterial DNA Gyrase (GyrB) inhibitor being developed for the treatment of nontuberculous mycobacterial pulmonary disease and pulmonary tuberculosis. SPR719 is the active form/moiety of SPR720.

Chemical Structure

img
SPR719
CAS# 1384984-18-2
Instruction

Theoretical Analysis

Hodoodo Cat#: H130282
Name: SPR719
CAS#: 1384984-18-2
Chemical Formula: C21H25FN6O3
Exact Mass: 428.20
Molecular Weight: 428.470
Elemental Analysis: C, 58.87; H, 5.88; F, 4.43; N, 19.61; O, 11.20

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SPR719; SPR 719; SPR-719; VXc-486; VXc 486; VXc486

IUPAC/Chemical Name: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea

InChi Key: BKUISYCLLXCBJV-CQSZACIVSA-N

InChi Code: InChI=1S/C21H25FN6O3/c1-4-23-20(29)28-19-26-13-8-12(11-9-24-18(25-10-11)21(2,3)30)16(22)15(17(13)27-19)14-6-5-7-31-14/h8-10,14,30H,4-7H2,1-3H3,(H3,23,26,27,28,29)/t14-/m1/s1

SMILES Code: O=C(NC1=NC2=CC(C3=CN=C(C(C)(O)C)N=C3)=C(F)C([C@@H]4OCCC4)=C2N1)NCC

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 428.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Madani A, Negatu DA, El Marrouni A, Miller RR, Boyce CW, Murgolo N, Bungard CJ, Zimmerman MD, Dartois V, Gengenbacher M, Olsen DB, Dick T. Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0066922. doi: 10.1128/aac.00669-22. Epub 2022 Aug 25. PMID: 36005813; PMCID: PMC9487482.

2. Aragaw WW, Cotroneo N, Stokes S, Pucci M, Critchley I, Gengenbacher M, Dick T. In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol Spectr. 2022 Feb 23;10(1):e0132121. doi: 10.1128/spectrum.01321-21. Epub 2022 Jan 12. PMID: 35019671; PMCID: PMC8754139.

3. Talley AK, Thurston A, Moore G, Gupta VK, Satterfield M, Manyak E, Stokes S, Dane A, Melnick D. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0120821. doi: 10.1128/AAC.01208-21. Epub 2021 Sep 7. PMID: 34491803; PMCID: PMC8525492.

4. Pidot SJ, Porter JL, Lister T, Stinear TP. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009636. doi: 10.1371/journal.pntd.0009636. PMID: 34310615; PMCID: PMC8341698.

5. Negatu DA, Beuchel A, Madani A, Alvarez N, Chen C, Aragaw WW, Zimmerman MD, Laleu B, Gengenbacher M, Dartois V, Imming P, Dick T. Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0067621. doi: 10.1128/AAC.00676-21. Epub 2021 Jul 16. PMID: 34001512; PMCID: PMC8284461.

6. Egorova A, Jackson M, Gavrilyuk V, Makarov V. Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. Med Res Rev. 2021 Jul;41(4):2350-2387. doi: 10.1002/med.21798. Epub 2021 Mar 1. PMID: 33645845; PMCID: PMC8217127.

7. Pennings LJ, Ruth MM, Wertheim HFL, van Ingen J. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02469-20. doi: 10.1128/AAC.02469-20. PMID: 33468478; PMCID: PMC8097464.

8. Brown-Elliott BA, Rubio A, Wallace RJ Jr. In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01503-18. doi: 10.1128/AAC.01503-18. PMID: 30126964; PMCID: PMC6201134.